Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 9/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL563602 | 0.92 | GCK (0.46) | GCKTBK1XDHHRH3SLC6A9 | |
| SCHEMBL564632 | 0.88 | GCK (0.43) | GCKKMT2ATBK1XDHHRH3 | |
| SCHEMBL563581 | 0.88 | GCK (0.39) | GCKTBK1HRH3SLC6A9BRD4 | |
| SCHEMBL563828 | 0.87 | GCK (0.39) | GCKKMT2A | |
| SCHEMBL1076457 | 0.86 | RORC (0.39) | GCKKMT2AXDHBRD4 | |
| SCHEMBL563680 | 0.83 | GCK (0.35) | GCKKMT2AHRH3BRD4KAT2B | |
| SCHEMBL1075126 | 0.82 | KDM4E (0.48) | GCKKMT2AXDH | |
| SCHEMBL13665672 | 0.81 | KMT2A (0.43) | GCKKMT2AXDH | |
| SCHEMBL564323 | 0.80 | GCK (0.42) | GCKTBK1 | |
| SCHEMBL564635 | 0.80 | GCK (0.39) | GCKTBK1HRH3SLC6A9BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557805-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-02-09 | — | — | US | disclosed |
| EP-2371826-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | GPR119, GCKR, SLC5A1 | GCK 5/4885KMT2A 1470/4885TBK1 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.